china pharma holdings inc (CPHI) Snapshot

China Pharma Holdings, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported revenue of $8,249,387 compared to $16,086,731 a year ago. The revenue decrease was primarily due to its continued tightened marketing strategy as well as the cessation of its product Buflomedil. Loss from operations was $3,000,459 compared to income from operations of $3,413,787 a year ago. The main reasons for the decrease were lower revenue, and the inventory obsolescence reserve recognized as a result of the CFDA notice on Buflomedil in the first quarter of 2013. Loss before income taxes was $3,081,318 compared to income before income taxes of $3,336,940 a year ago. Net loss was $2,812,307 or $0.06 per basic and diluted share compared to net income of $2,806,359 or $0.06 per basic and diluted share a year ago. The decrease in net income was mainly due to the decrease in revenue, and the inventory obsolescence reserve recognized as a result of the CFDA notice on Buflomedil. Net cash provided by operating activities was $1,107,749 compared to $401,380 a year ago. Purchase of property and equipment was $4,373 compared to $7,926 a year ago. Advances for purchases of property and equipment and intangible assets were $399,992 compared to $790,092 a year ago.

China Pharma Holdings, Inc., Q1 2013 Earnings Call, May 15, 2013

China Pharma Holdings, Inc. reported consolidated earnings results for the year ended December 31, 2012. For the year, the company has posted revenue was $54.5 million, dropped 33% from revenues of $81.2 million for the year ended December 31, 2011. This decrease was primarily from CNS Cerebral & Cardio Vascular product category in terms of the decrease in dollar amount and digestive disease product category in terms of percentage of decrease in revenues. Operating income was $5.9 million compared to $22.0 million in 2011, a decrease of 73%. The lower operating income in 2012 reflects lower revenue, lower gross profits and higher bad debt expenses in 2012. Net income was $4.6 million, or $0.11 per basic and diluted share, compared to $19.3 million, or $0.44 per basic and diluted share in 2011. Income before income tax was $5.60 million against $22.71 million a year ago. Net cash provided by operating activities was $3.64 million against $5.23 million a year ago. Advances for purchases of property and equipment were $1.61 million. Advances for purchases of intangible assets were $3.21 million against $5.19 million a year ago. Purchase of property and equipment was $0.156 million against $0.352 million a year ago.